LPA受容体
シグナル伝達経路
研究分野
阻害剤の選択性比較
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1315 | Ki16425 | <1 mg/mL | 94 mg/mL | 94 mg/mL |
| S2906 | Ki16198 | <1 mg/mL | 96 mg/mL | 35 mg/mL |
| S8345 | ONO-7300243 | <1 mg/mL | 92 mg/mL | 46 mg/mL |
| S6633 | AM 095 | <1 mg/mL | 91 mg/mL | 3 mg/mL |
| S3572 | BMS-986020 | <1 mg/mL | 97 mg/mL | '''97 mg/mL |
亜型選択性的な製品
LPA Receptor製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1315 |
Ki16425Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6. |
|
|
| S2906 |
Ki16198Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6. |
Pain behavior and EDG2 and Nav1.8 expression after intrathecal injection of LPA. A LPA decreased PWTs (n = 8), and this was attenuated by the EDG2 antagonist Ki16198. B, C LPA up regulated EDG2 expression in L4-6 DRGs (n = 6). D, E Nav1.8 expression on L4-6 DRGs increased after LPA injection (n = 6). *P<0.05, **P<0.01, ***P<0.001.
|
|
| S8345 |
ONO-7300243ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM. |
||
| S6633 |
AM 095AM095 is an antagonist of the LPA type 1 receptor with IC50 values of 0.98 and 0.73 μM for recombinant human and mouse LPA1, respectively. |
||
| S3572新 |
BMS-986020BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF). |
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1315 |
Ki16425Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM in RH7777 cell lines, respectively, shows no activity at LPA4, LPA5, LPA6. |
2021, 12(1):662 2020, 868:172886 2019, 379(1):65-72 |
|
| S2906 |
Ki16198Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activity at LPA4, LPA5, LPA6. |
2016, 32(5):445-54 |
Pain behavior and EDG2 and Nav1.8 expression after intrathecal injection of LPA. A LPA decreased PWTs (n = 8), and this was attenuated by the EDG2 antagonist Ki16198. B, C LPA up regulated EDG2 expression in L4-6 DRGs (n = 6). D, E Nav1.8 expression on L4-6 DRGs increased after LPA injection (n = 6). *P<0.05, **P<0.01, ***P<0.001.
|
| S8345 |
ONO-7300243ONO-7300243 is a novel, potent LPA1(Lysophosphatidic Acid Receptor) antagonist with an IC50 of 160 nM. |
2020, 868:172886 |
|
| S6633 |
AM 095AM095 is an antagonist of the LPA type 1 receptor with IC50 values of 0.98 and 0.73 μM for recombinant human and mouse LPA1, respectively. |
||
| S3572新 |
BMS-986020BMS-986020 (AM152, AP-3152 free acid) is a potent and selective antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986020 inhibits bile acid and phospholipid transporters with IC50 of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively. BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF). |
